The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A microcystin consisting of D-alanyl, L-leucyl, (3S)-3-methyl-D-beta-aspartyl,L-arginyl, 2S,3S,4E,6E,8S,9S)-3-amino-4,5,6,7-tetradehydro-9-methoxy-2,6,8-trimethyl-10-phenyldecanoyl, D-gamma-glutamyl, and 2,3-didehydro-N-methylalanyl residues joined into a 25-membered macrocycle. Produced by the cyanobacterium Microcystis aeruginosa, it is the most studied of the microcystins.
cyanoginosin LR results in increased expression of ABCC2 mRNA cyanoginosin LR inhibits the reaction [ABCC2 protein results in increased transport of 5(6)-carboxy-2',7'-dichlorofluorescein] ABCC2 protein results in increased export of cyanoginosin LR
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of ACTA2 mRNA; [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of ACTA2 protein cyanoginosin LR results in increased expression of ACTA2 mRNA cyanoginosin LR results in increased expression of ACTA2 protein
cyanoginosin LR results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in increased phosphorylation of AKT1 protein] cyanoginosin LR results in decreased expression of AKT1 mRNA; cyanoginosin LR results in decreased expression of AKT1 protein Wortmannin inhibits the reaction [cyanoginosin LR results in increased phosphorylation of AKT1 protein]
cyanoginosin LR results in decreased expression of ALB mRNA; cyanoginosin LR results in decreased expression of ALB protein cyanoginosin LR results in increased secretion of ALB protein cyanoginosin LR results in increased expression of ALB protein
4-phenylbutyric acid inhibits the reaction [cyanoginosin LR results in increased expression of ATG12 mRNA]; 4-phenylbutyric acid inhibits the reaction [cyanoginosin LR results in increased expression of ATG12 protein] cyanoginosin LR results in increased expression of ATG12 mRNA; cyanoginosin LR results in increased expression of ATG12 protein
4-phenylbutyric acid inhibits the reaction [cyanoginosin LR results in increased expression of ATG5 mRNA]; 4-phenylbutyric acid inhibits the reaction [cyanoginosin LR results in increased expression of ATG5 protein] cyanoginosin LR results in increased expression of ATG5 mRNA; cyanoginosin LR results in increased expression of ATG5 protein
cyanoginosin LR results in increased expression of BAX mRNA; cyanoginosin LR results in increased expression of BAX protein [Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of BAX protein
cyanoginosin LR results in increased expression of BCL2; cyanoginosin LR results in increased expression of BCL2 protein cyanoginosin LR results in decreased expression of BCL2 protein cyanoginosin LR results in increased phosphorylation of BCL2 protein [cyanoginosin LR co-treated with Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of BCL2 protein; Buthionine Sulfoximine promotes the reaction [cyanoginosin LR results in decreased expression of BCL2 protein] cyanoginosin LR results in increased expression of and results in increased phosphorylation of BCL2 protein [Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in decreased expression of BCL2 protein; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in decreased expression of BCL2 protein]
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of BDKRB2 mRNA cyanoginosin LR results in increased expression of BDKRB2 mRNA
4-methylumbelliferone 8-carbaldehyde inhibits the reaction [cyanoginosin LR results in increased expression of BECN1 protein]; CAMKK2 protein affects the reaction [cyanoginosin LR results in increased expression of BECN1 protein]; ERN1 protein affects the reaction [cyanoginosin LR results in increased expression of BECN1 protein]; STO 609 inhibits the reaction [cyanoginosin LR results in increased expression of BECN1 protein]
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of BEX1 mRNA cyanoginosin LR results in increased expression of BEX1 mRNA
BLK protein inhibits the reaction [cyanoginosin LR affects the localization of CGAS protein]; BLK protein inhibits the reaction [cyanoginosin LR inhibits the reaction [PARP1 protein binds to TIMELESS protein]]; BLK protein inhibits the reaction [cyanoginosin LR results in increased mutagenesis of HPRT1 gene]
cyanoginosin LR inhibits the reaction [Kainic Acid results in increased phosphorylation of CAMK2A protein] cyanoginosin LR results in increased phosphorylation of CAMK2A protein
CAMKK2 protein affects the reaction [cyanoginosin LR results in decreased expression of SQSTM1 protein]; CAMKK2 protein affects the reaction [cyanoginosin LR results in decreased phosphorylation of MTOR protein]; CAMKK2 protein affects the reaction [cyanoginosin LR results in increased expression of BECN1 protein]; STO 609 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of CAMKK2 protein]
cyanoginosin LR results in increased expression of and results in increased cleavage of CASP1 protein; FOXO1 affects the reaction [cyanoginosin LR affects the expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [cyanoginosin LR results in increased expression of and results in increased cleavage of CASP1 protein]
cyanoginosin LR results in increased activity of CASP3 protein sulforaphane inhibits the reaction [cyanoginosin LR results in increased activity of CASP3 protein] cyanoginosin LR results in increased expression of CASP3 mRNA; cyanoginosin LR results in increased expression of CASP3 protein cyanoginosin LR results in increased cleavage of CASP3 protein pifithrin inhibits the reaction [cyanoginosin LR results in increased cleavage of CASP3 protein]
cyanoginosin LR results in increased expression of CASP9 protein [cyanoginosin LR co-treated with Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CASP9 protein cyanoginosin LR results in increased activity of CASP9 protein
cyanoginosin LR results in decreased expression of CAT mRNA Quercetin inhibits the reaction [cyanoginosin LR results in increased activity of CAT protein] cyanoginosin LR results in decreased activity of CAT protein GCLC protein inhibits the reaction [cyanoginosin LR results in decreased activity of CAT protein]
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of CCL11 protein cyanoginosin LR results in decreased expression of CCL11 protein
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of CCL5 protein cyanoginosin LR results in increased expression of CCL5 mRNA
cyanoginosin LR results in increased expression of CCND1 mRNA; cyanoginosin LR results in increased expression of CCND1 protein cyanoginosin LR results in decreased expression of CCND1 mRNA; cyanoginosin LR results in decreased expression of CCND1 protein MK 2206 inhibits the reaction [cyanoginosin LR results in increased expression of CCND1 protein] Wortmannin inhibits the reaction [cyanoginosin LR results in increased expression of CCND1 protein]
cyanoginosin LR results in increased expression of CD24 mRNA [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of CD24 mRNA
cyanoginosin LR results in decreased expression of CDH1 mRNA; cyanoginosin LR results in decreased expression of CDH1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in decreased expression of CDH1 protein]; SMAD2 protein affects the reaction [cyanoginosin LR results in decreased expression of CDH1 protein]
cyanoginosin LR results in decreased expression of CDK4 mRNA; cyanoginosin LR results in decreased expression of CDK4 protein Wortmannin inhibits the reaction [cyanoginosin LR results in increased expression of CDK4 protein]
cyanoginosin LR results in increased expression of CDKN1A protein cyanoginosin LR results in increased expression of CDKN1A mRNA pifithrin inhibits the reaction [cyanoginosin LR results in increased expression of CDKN1A protein] cyanoginosin LR results in decreased expression of CDKN1A protein
cyanoginosin LR results in increased expression of CGAS mRNA; cyanoginosin LR results in increased expression of CGAS protein [cyanoginosin LR inhibits the reaction [PARP1 protein binds to TIMELESS protein]] promotes the reaction [CGAS protein binds to PARP1 protein]; BLK protein inhibits the reaction [cyanoginosin LR affects the localization of CGAS protein]; cyanoginosin LR promotes the reaction [CGAS protein binds to PARP1 protein]; cyanoginosin LR results in increased expression of and affects the localization of CGAS protein
cyanoginosin LR results in decreased expression of CLDN5 protein [cyanoginosin LR co-treated with LCN2 protein] results in decreased expression of CLDN5 protein; [Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in decreased expression of CLDN5 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[cyanoginosin LR co-treated with LCN2 protein] results in decreased expression of CLDN5 protein]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in decreased expression of CLDN5 protein]]
cyanoginosin LR inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA] cyanoginosin LR results in decreased expression of CSF2 mRNA; cyanoginosin LR results in decreased expression of CSF2 protein
cyanoginosin LR results in increased expression of CX3CL1 protein [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of CX3CL1 protein
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of CXCL1 protein cyanoginosin LR results in decreased expression of CXCL1 protein
cyanoginosin LR results in decreased expression of CXCL2 protein [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of CXCL2 protein cyanoginosin LR results in increased expression of CXCL2 mRNA
cyanoginosin LR results in increased expression of CXCL5 mRNA [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of CXCL5 protein
allyl sulfide inhibits the reaction [cyanoginosin LR results in increased expression of CYP2E1 mRNA]; Chlormethiazole inhibits the reaction [cyanoginosin LR results in increased expression of CYP2E1 mRNA]; sulforaphane inhibits the reaction [cyanoginosin LR results in increased expression of CYP2E1 mRNA]; sulforaphane inhibits the reaction [cyanoginosin LR results in increased expression of CYP2E1 protein]; Thioctic Acid affects the reaction [cyanoginosin LR affects the expression of CYP2E1 protein] cyanoginosin LR results in increased expression of CYP2E1 mRNA; cyanoginosin LR results in increased expression of CYP2E1 protein
4-phenylbutyric acid inhibits the reaction [cyanoginosin LR results in increased phosphorylation of EIF2AK3 protein]; [cyanoginosin LR co-treated with Kainic Acid] results in increased phosphorylation of EIF2AK3 protein
cyanoginosin LR results in increased expression of EPCAM mRNA [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of EPCAM mRNA
4-methylumbelliferone 8-carbaldehyde inhibits the reaction [cyanoginosin LR results in increased phosphorylation of ERN1 protein]; ERN1 protein affects the reaction [cyanoginosin LR results in increased expression of BECN1 protein]; ERN1 protein affects the reaction [cyanoginosin LR results in increased expression of XBP1 protein alternative form]
cyanoginosin LR results in increased expression of EZR mRNA [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which results in increased expression of EZR protein modified form; SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of EZR protein]; U 0126 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of EZR protein]
cyanoginosin LR results in increased expression of FERMT1 mRNA [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of FERMT1 mRNA
cyanoginosin LR results in increased expression of FOS mRNA cyanoginosin LR results in increased expression of FOS mRNA; cyanoginosin LR results in increased expression of FOS protein
cyanoginosin LR results in increased phosphorylation of and results in decreased localization of and results in decreased activity of FOXO1 protein; FOXO1 affects the reaction [cyanoginosin LR affects the expression of CASP1 protein]; FOXO1 affects the reaction [cyanoginosin LR results in increased expression of NLRP3 protein]; perifosine inhibits the reaction [cyanoginosin LR results in increased phosphorylation of FOXO1 protein]; PPP2CA protein affects the reaction [cyanoginosin LR results in increased phosphorylation of FOXO1 protein] cyanoginosin LR results in decreased phosphorylation of FOXO1 protein
cyanoginosin LR results in increased expression of GCLC mRNA cyanoginosin LR results in decreased expression of GCLC mRNA cyanoginosin LR results in decreased expression of and results in increased phosphorylation of GCLC protein; GCLC protein inhibits the reaction [cyanoginosin LR results in decreased activity of CAT protein]
cyanoginosin LR results in increased expression of and results in increased phosphorylation of GRIA1 protein; Kainic Acid inhibits the reaction [cyanoginosin LR results in increased expression of and results in increased phosphorylation of GRIA1 protein]
cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of and results in decreased activity of GSK3A protein]; cyanoginosin LR results in increased phosphorylation of and results in decreased activity of GSK3A protein; INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of and results in decreased activity of GSK3A protein] cyanoginosin LR results in increased phosphorylation of GSK3A protein
cyanoginosin LR results in increased phosphorylation of GSK3B protein cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of and results in decreased activity of GSK3B protein]; cyanoginosin LR results in increased expression of and results in increased phosphorylation of GSK3B protein; cyanoginosin LR results in increased phosphorylation of and results in decreased activity of GSK3B protein; INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of and results in decreased activity of GSK3B protein]; Metformin inhibits the reaction [cyanoginosin LR results in increased phosphorylation of GSK3B protein]; MK 2206 inhibits the reaction [cyanoginosin LR results in increased expression of and results in increased phosphorylation of GSK3B protein]
cyanoginosin LR results in increased expression of GSR mRNA cyanoginosin LR results in increased activity of GSR protein [cyanoginosin LR co-treated with Buthionine Sulfoximine] results in increased activity of GSR protein Thioctic Acid inhibits the reaction [cyanoginosin LR results in decreased activity of GSR protein]
GSTA1 protein results in increased glutathionylation of and affects the susceptibility to cyanoginosin LR cyanoginosin LR results in decreased expression of GSTA1 mRNA
GSTM1 protein results in increased glutathionylation of and affects the susceptibility to cyanoginosin LR cyanoginosin LR results in decreased expression of GSTM1 mRNA cyanoginosin LR results in increased expression of GSTM1 mRNA; cyanoginosin LR results in increased expression of GSTM5 mRNA
cyanoginosin LR results in increased expression of and results in increased phosphorylation of and results in decreased activity of GYS1 protein cyanoginosin LR inhibits the reaction [INS protein results in decreased phosphorylation of and results in increased activity of GYS1 protein]; cyanoginosin LR results in increased expression of and results in increased phosphorylation of and results in decreased activity of GYS1 protein
cyanoginosin LR results in increased expression of HIF1A protein Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of HIF1A protein]
cyanoginosin LR results in increased expression of HMGB1 protein [Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in increased expression of HMGB1 protein]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in increased expression of HMGB1 protein]]
[cyanoginosin LR affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; cyanoginosin LR promotes the reaction [sulforaphane results in increased expression of HMOX1 protein]; NFE2L2 protein affects the susceptibility to [cyanoginosin LR results in increased expression of HMOX1 protein] cyanoginosin LR results in increased expression of HMOX1 mRNA; cyanoginosin LR results in increased expression of HMOX1 protein
cyanoginosin LR results in increased mutagenesis of HPRT1 gene BLK protein inhibits the reaction [cyanoginosin LR results in increased mutagenesis of HPRT1 gene]
cyanoginosin LR results in increased expression of HSPB1 mRNA cyanoginosin LR results in increased phosphorylation of HSPB1 protein SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of HSPB1 protein]
cyanoginosin LR inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA] cyanoginosin LR results in decreased expression of IFNG protein [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of IFNG mRNA; [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of IFNG protein
[IGBP1 protein results in increased susceptibility to cyanoginosin LR] which affects the expression of PPP2CA protein modified form; [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which affects the expression of VASP protein modified form; [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which results in increased expression of EZR protein modified form; [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which results in increased expression of PPP2CA protein; [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which results in increased phosphorylation of MAPK1 protein; [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which results in increased phosphorylation of MAPK3 protein; [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which results in increased phosphorylation of MAPK8 protein; [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which results in increased phosphorylation of MAPK9 protein; cyanoginosin LR inhibits the reaction [IGBP1 protein binds to PPP2CA protein]; cyanoginosin LR inhibits the reaction [PPP2CA protein binds to IGBP1 protein] IGBP1 protein affects the susceptibility to cyanoginosin LR
cyanoginosin LR results in decreased expression of IL10 protein [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of IL10 mRNA; [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of IL10 protein cyanoginosin LR results in decreased secretion of IL10 protein
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of IL17A protein cyanoginosin LR results in decreased expression of IL17A protein cyanoginosin LR results in increased secretion of IL17A protein
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of IL18 protein cyanoginosin LR results in increased expression of IL18 protein
[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of IL1B protein; cyanoginosin LR inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; LCN2 protein promotes the reaction [cyanoginosin LR results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [cyanoginosin LR results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [LCN2 protein promotes the reaction [cyanoginosin LR results in increased secretion of IL1B protein]]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of IL1B protein] cyanoginosin LR results in increased expression of IL1B protein cyanoginosin LR results in increased expression of IL1B mRNA [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of IL1B protein
cyanoginosin LR results in decreased expression of IL2 protein [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of IL2 protein
cyanoginosin LR results in increased expression of IL22RA1 mRNA [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of IL22RA1 mRNA
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of IL4 protein cyanoginosin LR results in decreased expression of IL4 protein
cyanoginosin LR results in increased expression of IL6 mRNA; cyanoginosin LR results in increased expression of IL6 protein cyanoginosin LR promotes the reaction [TNF protein results in increased expression of and results in increased secretion of IL6 protein]; cyanoginosin LR results in increased expression of and results in increased secretion of IL6 protein cyanoginosin LR results in decreased expression of IL6 protein [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of IL6 protein cyanoginosin LR results in increased secretion of IL6 protein
cyanoginosin LR inhibits the reaction [INS protein results in decreased phosphorylation of and results in increased activity of GYS1 protein]; cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]; cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of and results in decreased activity of GSK3A protein]; cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of and results in decreased activity of GSK3B protein]; cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]; INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]; INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of and results in decreased activity of GSK3A protein]; INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of and results in decreased activity of GSK3B protein]; INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]]
cyanoginosin LR results in increased phosphorylation of IRS1 protein cyanoginosin LR results in decreased expression of and results in increased phosphorylation of IRS1 protein cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]; INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]] cyanoginosin LR results in decreased phosphorylation of IRS1 protein cyanoginosin LR results in decreased expression of IRS1 mRNA
cyanoginosin LR results in decreased expression of IRS2 mRNA; cyanoginosin LR results in decreased expression of IRS2 protein cyanoginosin LR results in decreased phosphorylation of IRS2 protein
cyanoginosin LR results in increased expression of JUN mRNA cyanoginosin LR results in increased phosphorylation of JUN protein cyanoginosin LR results in increased expression of JUN mRNA; cyanoginosin LR results in increased expression of JUN protein
cyanoginosin LR results in decreased expression of KDR protein [cyanoginosin LR co-treated with 2-tert-butylhydroquinone] results in increased expression of KDR protein
cyanoginosin LR results in increased expression of KRT18 mRNA SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of KRT18 protein]; U 0126 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of KRT18 protein]
cyanoginosin LR results in increased phosphorylation of and affects the expression of KRT8 protein; SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of KRT8 protein]; U 0126 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of KRT8 protein] cyanoginosin LR results in increased expression of KRT8 mRNA
4-methylumbelliferone 8-carbaldehyde inhibits the reaction [cyanoginosin LR results in increased expression of LAMP1 protein]; STO 609 inhibits the reaction [cyanoginosin LR results in increased expression of LAMP1 protein]
cyanoginosin LR results in increased expression of LCN2 protein [cyanoginosin LR co-treated with LCN2 protein] results in decreased expression of CLDN5 protein; [cyanoginosin LR co-treated with LCN2 protein] results in decreased expression of TJP1 protein; [cyanoginosin LR co-treated with LCN2 protein] results in increased secretion of S100B protein; [Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in increased expression of LCN2 protein]; FPS-ZM1 inhibits the reaction [[cyanoginosin LR co-treated with LCN2 protein] results in increased secretion of S100B protein]; LCN2 protein promotes the reaction [cyanoginosin LR results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[cyanoginosin LR co-treated with LCN2 protein] results in decreased expression of CLDN5 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[cyanoginosin LR co-treated with LCN2 protein] results in decreased expression of TJP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [LCN2 protein promotes the reaction [cyanoginosin LR results in increased secretion of IL1B protein]]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in increased expression of LCN2 protein]]
cyanoginosin LR results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in increased phosphorylation of MAPK1 protein]; [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which results in increased phosphorylation of MAPK1 protein; cyanoginosin LR promotes the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] cyanoginosin LR promotes the reaction [Kainic Acid results in increased phosphorylation of MAPK1 protein] cyanoginosin LR results in decreased phosphorylation of MAPK1 protein
cyanoginosin LR results in increased phosphorylation of and results in increased activity of MAPK14 protein cyanoginosin LR results in increased phosphorylation of MAPK14 protein
cyanoginosin LR results in increased expression of MAPK3 mRNA cyanoginosin LR results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in increased phosphorylation of MAPK3 protein]; [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which results in increased phosphorylation of MAPK3 protein; cyanoginosin LR promotes the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] cyanoginosin LR promotes the reaction [Kainic Acid results in increased phosphorylation of MAPK3 protein] cyanoginosin LR results in decreased phosphorylation of MAPK3 protein
cyanoginosin LR results in increased expression of MAPK9 mRNA [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which results in increased phosphorylation of MAPK9 protein
cyanoginosin LR affects the phosphorylation of MAPT protein cyanoginosin LR results in increased localization of MAPT protein Acetylcysteine inhibits the reaction [cyanoginosin LR results in increased phosphorylation of MAPT protein]; Ascorbic Acid inhibits the reaction [cyanoginosin LR results in increased phosphorylation of MAPT protein]; SB 203580 inhibits the reaction [cyanoginosin LR results in increased localization of MAPT protein]; SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of MAPT protein]
cyanoginosin LR results in increased expression of and results in increased phosphorylation of MCM2 protein cyanoginosin LR results in increased expression of MCM2 protein
cyanoginosin LR results in increased expression of MMP14 mRNA; cyanoginosin LR results in increased expression of MMP14 protein Wortmannin inhibits the reaction [cyanoginosin LR results in increased expression of MMP14 protein]
cyanoginosin LR results in increased expression of MMP9 mRNA; cyanoginosin LR results in increased expression of MMP9 protein cyanoginosin LR results in decreased expression of MMP9 protein [Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in increased expression of MMP9 protein]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in increased expression of MMP9 protein]]
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of MSLN mRNA cyanoginosin LR results in increased expression of MSLN mRNA
cyanoginosin LR results in increased expression of MTOR protein cyanoginosin LR results in decreased phosphorylation of MTOR protein CAMKK2 protein affects the reaction [cyanoginosin LR results in decreased phosphorylation of MTOR protein]; cyanoginosin LR results in increased expression of and results in increased phosphorylation of MTOR protein; Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of MTOR protein]; STO 609 inhibits the reaction [cyanoginosin LR results in decreased phosphorylation of MTOR protein]; Wortmannin inhibits the reaction [cyanoginosin LR results in increased phosphorylation of MTOR protein]
cyanoginosin LR results in increased expression of MYC mRNA; cyanoginosin LR results in increased expression of MYC protein cyanoginosin LR results in increased phosphorylation of MYC protein Wortmannin inhibits the reaction [cyanoginosin LR results in increased expression of MYC protein]
[cyanoginosin LR affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; [cyanoginosin LR affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; cyanoginosin LR inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of NFE2L2 protein]; cyanoginosin LR promotes the reaction [sulforaphane affects the localization of NFE2L2 protein]; cyanoginosin LR results in increased expression of and results in increased activity of and affects the localization of NFE2L2 protein; NFE2L2 protein affects the susceptibility to [cyanoginosin LR results in increased expression of HMOX1 protein]; NFE2L2 protein affects the susceptibility to [cyanoginosin LR results in increased expression of NQO1 protein] cyanoginosin LR results in decreased degradation of NFE2L2 protein NFE2L2 protein affects the susceptibility to cyanoginosin LR cyanoginosin LR affects the expression of NFE2L2 protein [Thioctic Acid co-treated with cyanoginosin LR] results in increased expression of NFE2L2 protein
cyanoginosin LR promotes the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] cyanoginosin LR results in increased phosphorylation of NFKBIA protein
cyanoginosin LR results in increased expression of NLRP3 protein FOXO1 affects the reaction [cyanoginosin LR results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in decreased expression of BCL2 protein]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of IL1B protein]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of NOS2 protein]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of PTGS2 protein]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of S100B protein]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in decreased expression of CLDN5 protein]]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in decreased expression of TJP1 protein]]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in increased expression of HMGB1 protein]]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in increased expression of LCN2 protein]]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in increased expression of MMP9 protein]]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in increased expression of TNF protein]]; NLRP3 protein affects the reaction [cyanoginosin LR results in increased expression of NOS2 protein]
[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of NOS2 protein; cyanoginosin LR inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of NOS2 protein]; NLRP3 protein affects the reaction [cyanoginosin LR results in increased expression of NOS2 protein]
cyanoginosin LR results in increased expression of NQO1 mRNA [cyanoginosin LR affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; cyanoginosin LR promotes the reaction [sulforaphane results in increased expression of NQO1 protein]; NFE2L2 protein affects the susceptibility to [cyanoginosin LR results in increased expression of NQO1 protein] cyanoginosin LR results in increased expression of NQO1 mRNA; cyanoginosin LR results in increased expression of NQO1 protein
cyanoginosin LR results in increased expression of NRAS mRNA cyanoginosin LR results in increased expression of NRAS mRNA; cyanoginosin LR results in increased expression of NRAS protein
cyanoginosin LR results in increased expression of NTS mRNA [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of NTS mRNA
cyanoginosin LR results in increased expression of PAPPA mRNA cyanoginosin LR results in decreased expression of PAPPA mRNA; cyanoginosin LR results in decreased expression of PAPPA protein
cyanoginosin LR results in increased cleavage of PARP1 protein sulforaphane inhibits the reaction [cyanoginosin LR results in increased cleavage of PARP1 protein] pifithrin inhibits the reaction [cyanoginosin LR results in increased cleavage of PARP1 protein] [cyanoginosin LR inhibits the reaction [PARP1 protein binds to TIMELESS protein]] promotes the reaction [CGAS protein binds to PARP1 protein]; BLK protein inhibits the reaction [cyanoginosin LR inhibits the reaction [PARP1 protein binds to TIMELESS protein]]; cyanoginosin LR inhibits the reaction [PARP1 protein binds to TIMELESS protein]; cyanoginosin LR promotes the reaction [CGAS protein binds to PARP1 protein]
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of PDGFD mRNA cyanoginosin LR results in increased expression of PDGFD mRNA
cyanoginosin LR results in increased expression of PIK3CA protein Wortmannin inhibits the reaction [cyanoginosin LR results in increased expression of PIK3CA protein]
cyanoginosin LR binds to PPP2CA protein cyanoginosin LR results in increased phosphorylation of and results in decreased activity of PPP2CA protein [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which affects the expression of PPP2CA protein modified form; [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which results in increased expression of PPP2CA protein; cyanoginosin LR inhibits the reaction [IGBP1 protein binds to PPP2CA protein]; cyanoginosin LR inhibits the reaction [PPP2CA protein binds to IGBP1 protein]; cyanoginosin LR inhibits the reaction [PPP2CA protein binds to PPP2R1A protein]; cyanoginosin LR inhibits the reaction [PPP2R1A protein binds to PPP2CA protein]; cyanoginosin LR results in increased expression of and results in increased phosphorylation of and results in increased methylation of PPP2CA protein PPP2CA protein affects the reaction [cyanoginosin LR results in increased phosphorylation of FOXO1 protein]
cyanoginosin LR results in increased expression of PPP2R1A protein cyanoginosin LR inhibits the reaction [PPP2CA protein binds to PPP2R1A protein]; cyanoginosin LR inhibits the reaction [PPP2R1A protein binds to PPP2CA protein] cyanoginosin LR results in decreased expression of PPP2R1A protein
cyanoginosin LR affects the expression of PPP2R2A protein cyanoginosin LR results in increased expression of and affects the localization of PPP2R2A protein cyanoginosin LR results in decreased expression of PPP2R2A protein
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of PROM1 mRNA cyanoginosin LR results in increased expression of PROM1 mRNA
cyanoginosin LR results in increased expression of PTGS2 mRNA; cyanoginosin LR results in increased expression of PTGS2 protein [Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of PTGS2 protein; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of PTGS2 protein]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of PTGS2 protein]
cyanoginosin LR results in increased expression of PTK7 mRNA [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of PTK7 mRNA
cyanoginosin LR results in increased activity of RELA protein cyanoginosin LR results in increased phosphorylation of RELA protein Ethidium inhibits the reaction [cyanoginosin LR results in increased phosphorylation of RELA protein]
cyanoginosin LR results in increased phosphorylation of RPS6KB1 protein naringin inhibits the reaction [cyanoginosin LR results in increased phosphorylation of RPS6KB1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in increased phosphorylation of RPS6KB1 protein]; cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]; INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]; Metformin inhibits the reaction [cyanoginosin LR results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]]
[cyanoginosin LR co-treated with LCN2 protein] results in increased secretion of S100B protein; [Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of S100B protein; FPS-ZM1 inhibits the reaction [[cyanoginosin LR co-treated with LCN2 protein] results in increased secretion of S100B protein]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of S100B protein]
cyanoginosin LR results in increased expression of SEMA3A mRNA [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of SEMA3A mRNA
cyanoginosin LR results in decreased expression of SLCO1B2 mRNA SLCO1B2 results in increased susceptibility to cyanoginosin LR SLCO1B2 protein affects the susceptibility to cyanoginosin LR SLCO1B3 protein results in increased susceptibility to cyanoginosin LR SLCO1B3 protein results in increased uptake of cyanoginosin LR Cyclosporine inhibits the reaction [SLCO1B3 protein results in increased import of cyanoginosin LR]; Dehydroepiandrosterone Sulfate inhibits the reaction [SLCO1B3 protein results in increased susceptibility to cyanoginosin LR]; Okadaic Acid inhibits the reaction [SLCO1B3 protein results in increased uptake of cyanoginosin LR]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased import of cyanoginosin LR]; Sulfobromophthalein inhibits the reaction [SLCO1B3 protein results in increased import of cyanoginosin LR]; Sulfobromophthalein inhibits the reaction [SLCO1B3 protein results in increased susceptibility to cyanoginosin LR]; Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to cyanoginosin LR] [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of SLCO1B2 protein cyanoginosin LR results in decreased expression of SLCO1B2 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in increased phosphorylation of SMAD2 protein]; cyanoginosin LR results in increased expression of and results in increased phosphorylation of SMAD2 protein; SMAD2 protein affects the reaction [cyanoginosin LR results in decreased expression of CDH1 protein]; SMAD2 protein affects the reaction [cyanoginosin LR results in increased expression of SNAI1 protein]; SMAD2 protein affects the reaction [cyanoginosin LR results in increased expression of VIM protein]
cyanoginosin LR results in increased expression of SNAI1 mRNA; cyanoginosin LR results in increased expression of SNAI1 protein SMAD2 protein affects the reaction [cyanoginosin LR results in increased expression of SNAI1 protein]
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of SNCG mRNA cyanoginosin LR results in increased expression of SNCG mRNA
4-methylumbelliferone 8-carbaldehyde inhibits the reaction [cyanoginosin LR results in decreased expression of SQSTM1 protein]; CAMKK2 protein affects the reaction [cyanoginosin LR results in decreased expression of SQSTM1 protein]; STO 609 inhibits the reaction [cyanoginosin LR results in decreased expression of SQSTM1 protein] cyanoginosin LR results in increased expression of SQSTM1 mRNA
cyanoginosin LR results in increased expression of SRPX2 mRNA [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of SRPX2 mRNA
cyanoginosin LR results in increased phosphorylation of STAT3 protein cyanoginosin LR results in increased expression of and results in increased phosphorylation of STAT3 protein
Ethidium inhibits the reaction [cyanoginosin LR results in increased expression of STING1 protein] cyanoginosin LR results in increased expression of STING1 mRNA; cyanoginosin LR results in increased expression of STING1 protein
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of TGFB3 mRNA cyanoginosin LR results in increased expression of TGFB3 mRNA
cyanoginosin LR results in decreased expression of TIMELESS protein [cyanoginosin LR inhibits the reaction [PARP1 protein binds to TIMELESS protein]] promotes the reaction [CGAS protein binds to PARP1 protein]; BLK protein inhibits the reaction [cyanoginosin LR inhibits the reaction [PARP1 protein binds to TIMELESS protein]]; cyanoginosin LR inhibits the reaction [PARP1 protein binds to TIMELESS protein]
cyanoginosin LR results in decreased expression of TJP1 protein [cyanoginosin LR co-treated with LCN2 protein] results in decreased expression of TJP1 protein; [cyanoginosin LR co-treated with N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide] results in increased expression of TJP1 protein; [Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in decreased expression of TJP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[cyanoginosin LR co-treated with LCN2 protein] results in decreased expression of TJP1 protein]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in decreased expression of TJP1 protein]]
cyanoginosin LR promotes the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; cyanoginosin LR promotes the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]; cyanoginosin LR promotes the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] [Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in increased expression of TNF protein]; cyanoginosin LR inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; cyanoginosin LR promotes the reaction [TNF protein results in increased expression of and results in increased secretion of IL6 protein]; Ethidium inhibits the reaction [cyanoginosin LR results in increased expression of TNF mRNA]; NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats] promotes the reaction [cyanoginosin LR results in increased expression of TNF protein]]; sulforaphane inhibits the reaction [cyanoginosin LR results in increased expression of TNF mRNA] cyanoginosin LR results in decreased expression of TNF mRNA cyanoginosin LR results in increased expression of TNF mRNA; cyanoginosin LR results in increased expression of TNF protein cyanoginosin LR results in increased secretion of TNF protein
cyanoginosin LR results in increased expression of TP53; cyanoginosin LR results in increased expression of TP53 mRNA; cyanoginosin LR results in increased expression of TP53 protein cyanoginosin LR results in increased phosphorylation of TP53 protein cyanoginosin LR results in increased phosphorylation of TRP53 protein cyanoginosin LR results in increased expression of TRP53 protein [cyanoginosin LR co-treated with Buthionine Sulfoximine] results in increased expression of TP53 protein; pifithrin inhibits the reaction [cyanoginosin LR results in increased expression of TP53 protein]
cyanoginosin LR results in increased phosphorylation of VASP protein [IGBP1 protein results in increased susceptibility to cyanoginosin LR] which affects the expression of VASP protein modified form; cyanoginosin LR results in increased phosphorylation of and affects the localization of VASP protein; SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of VASP protein]; U 0126 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of VASP protein]
[Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in decreased expression of VEGFA protein cyanoginosin LR results in decreased expression of VEGFA protein Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of VEGFA protein]
cyanoginosin LR results in increased expression of VEGFD mRNA [Dietary Fats co-treated with Cholesterol, Dietary co-treated with cyanoginosin LR] results in increased expression of VEGFD mRNA
cyanoginosin LR results in increased phosphorylation of VIM protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in decreased expression of VIM protein]; SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of VIM protein]; SMAD2 protein affects the reaction [cyanoginosin LR results in increased expression of VIM protein]; U 0126 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of VIM protein] cyanoginosin LR results in increased expression of VIM mRNA cyanoginosin LR affects the localization of VIM protein
4-methylumbelliferone 8-carbaldehyde inhibits the reaction [cyanoginosin LR results in increased expression of XBP1 protein alternative form]; ERN1 protein affects the reaction [cyanoginosin LR results in increased expression of XBP1 protein alternative form]